Memphasys (ASX: MEM) Felix System Findings
Memphasys (ASX: MEM) has announced the first publications of study findings by key opinion leaders of the Felix System.
Watch Now
Memphasys Limited
Memphasys Ltd (ASX: MEM) is an Australian publicly-listed bio-separations company developing and commercialising innovative separation techniques based on the Company’s proprietary membrane technology.
Memphasys’ first application of this technology platform is now being commercialised – the separation of the ‘best’ sperm from a semen sample for use in human in vitro fertilisation (IVF).
Spotlight Videos
Memphasys Ltd – ShareCafe Hidden Gems Webinar Presentation
Memphasys Ltd CEO and Executive Chairman Alison Coutts presents at the ShareCafe Hidden Gems Webinar on June 26, 2020. Memphasys is an Australian publicly-listed bio-separations company developing and commercialising innovative separation techniques based on the Company’s proprietary membrane technology.
Watch Now
Q&A With Memphasys Executive Chair Alison Coutts
Memphasys' Executive Chair, Alison Coutts, was interviewed at the Finance News Network Investor Event on November 29 2019. The interview and presentation can be viewed by clicking the above link.
Watch Now
Professor John Aitken – Felix Device Interview
Professor John Aitken, PhD, ScD, FRSE, Head of the Medical Faculty at Newcastle University, Australia, and a global leader in Assisted Reproductive Technology (ART) research is interviewed about the Felix Device and its potential application in the area of male infertility and the future needs globally of the IVF and ART industries.
Watch Now
